Wow, this is truly a "game changer". I have written an article on the device (for my class), below. However, after reading new information about what has transpired, certainly raises concerns, although anytime there are electronics involved, there is alway an unfortunate chance of negative impacts. Sad
The healthcare industry faces more changes and challenges than any other business, and being centered around patient care,must be able to meet and assist with improving the lives of their patients. Patients who are diagnosed with a chronic illness and/or disease often finds it difficult to accept and display optimism with future care. As of 2015, the American Diabetes Association reported the following information regarding the disease (“American Diabetes Association”, 1995-2019):
- 9.4% (30.3 million) of the population in the United States are diagnosed with the disease, with 1.25 million of the population being adults and children (Type 1).
- 1.5 million cases are diagnosed each year
- 7.2 million people go undiagnosed
- 84.1 million Americans (18 or older), experienced prediabetes
In the United States, diabetes is the 7th major case of death, and by empowering those diagnosed with education on the disease, proper nutrition and exercise, along with medication management, can patients live a healthy lifestyle with the disease. Type 1 diabetes results when a person’s blood glucose is too low or does not have enough insulin to sustain, thus resulting in the use of medication (insulin), involving the use of a needle. A breakthrough in healthcare technology has developed by construction of a medical device called “The Artificial Pancreas Device System” (“U.S. Food and Drug Administration”, 2018), which automatically delivers insulin to a person’s body, helping to regulate their blood sugar (glucose).
Approved by the Food and Drug Administration (FDA), the first hybrid closes loop system called the “Medtronic MiniMed 670G System was introduced on September 28, 2016 ‘U.S. Food and Drug Administration”, 2018), that monitors the glucose level of its user and self-regulates insulin to the user, as needed. A uniqueness of this device is that it also stops the delivery of insulin when it detects that the users blood sugar (glucose) is too low. Because of its effectiveness with people diagnosed with Type 1 diabetes, this device now serves the same effectiveness with those having Type 2 diabetes (“National Institute for Health Research”, 2015).
American Diabetes Association (1995-2019). Retrieved from http://diabetes.org/diabetes-basics/statistics/
National Institute for Health Research (2015). Retrieved from https://discover.dc.nihr.ac.uk/content/signal-000675/type-2-diabetes-control-improves-with-artificial-pancreas
U.S. Food and Drug Administration (2018). Retrieved from https://www.fda.gov/medical-devices/consumer-products/artificial-pancreas-device-system